Condition
Thyroid Associated Ophthalmopathies clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Thyroid Associated Ophthalmopathies clinical trials that are recruiting, in China. By phase: Phase 4 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest Thyroid Associated Ophthalmopathies clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| AI-based MRI and ultrasound for thyroid-related eye disease | — | Shanghai, Huangpu District | Recruiting | Jul 21, 2026 |
| Eye movement and visual attention in people with thyroid-associated eye disease | — | Shanghai | Recruiting | Feb 2, 2026 |
| IBI311 for inactive thyroid‑related eye disease (TAO) | Phase 4 | Shanghai, Shanghai Municipality | Recruiting | Sep 3, 2025 |
| Sequential hormone therapy followed by tetuzumab for moderate-to-severe active thyroid eye disease after steroid treatment | Phase 4 | Shanghai, Shanghai Municipality | Recruiting | Sep 3, 2025 |
| Sequential glucocorticoid therapy followed by IBI311 for active moderate-to-severe thyroid eye disease | Phase 4 | Changhua, Shanghai Municipality and 1 other locations | Recruiting | Sep 3, 2025 |
All recruiting trials (5)
-
AI-based MRI and ultrasound for thyroid-related eye disease
This study tests an AI model using orbital MRI and eye ultrasound to help diagnose activity and severity of thyroid-associated ophthalmopathy and predict its course in adults.
-
Eye movement and visual attention in people with thyroid-associated eye disease
This project uses non-invasive eye tracking to test whether people with thyroid-associated ophthalmopathy track moving objects and scan faces differently than healthy volunteers.
-
IBI311 for inactive thyroid‑related eye disease (TAO)
This trial tests whether IBI311, an anti–IGF‑1R antibody, can help people with inactive moderate-to-severe thyroid‑associated ophthalmopathy who still have symptoms or need further surgery.
-
Sequential hormone therapy followed by tetuzumab for moderate-to-severe active thyroid eye disease after steroid treatment
This trial will test whether adding tetuzumab after prior steroid treatment helps people with moderate-to-severe active thyroid eye disease.
-
Sequential glucocorticoid therapy followed by IBI311 for active moderate-to-severe thyroid eye disease
This trial tests whether giving standard glucocorticoids followed by the anti-IGF-1R antibody IBI311 helps adults with active moderate-to-severe thyroid-associated ophthalmopathy (TAO).
Related topics
Quick answers
How many Thyroid Associated Ophthalmopathies clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 4: 3. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.